HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Francis, J. Articles by Finkelstein, F. O. Search for Related Content PubMed Articles by Francis, J. Articles by Finkelstein, F. O.

CALCIMIMETICS FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PERITONEAL DIALYSIS PATIENTS

Department of Internal Medicine, Division of Nephrology, Hospital of St. Raphael, Yale University, and the Renal Research institute, New Haven, Connecticut, U.S.A.

Correspondence to: F.O. Finkelstein, 136 Sherman Avenue, New Haven, Connecticut 06511 U.S.A. fof{at}comcast.net

Secondary hyperparathyroidism is a common complication in patients with end-stage renal disease. It has been associated with increased cardiovascular events and mortality. Traditional therapy has been based on vitamin D analogs and phosphate binders; but these therapies often do not control secondary hyperparathyroidism, particularly in peritoneal dialysis patients for whom phosphate clearances are limited and intravenous vitamin D is impractical. Cinacalcet, a calcimimetic, suppresses parathormone secretion by interacting with the calcium-sensing receptor on the surface of parathyroid gland cells. The resulting suppression of parathyroid hormone secretion produces a reduction in serum phosphate level and CaxPO₄ product. The present paper reviews the efficacy of cinacalcet in the management of secondary hyperparathyroidism in peritoneal dialysis patients.

KEY WORDS: Cinacalcet; calcimimetics; secondary hyperparathyroidism.

Copyright © 2008 by Multimed Inc.